Controlling HCV infection by targeting its translation initiation site in PBMCs using siRNA; In Vitro.

Controlling HCV infection by targeting its translation initiation site in PBMCs using siRNA; In Vitro. Infect Disord Drug Targets. 2018 Nov 14;: Authors: Youssef SS, Elemeery MN, Eldein SS, Ghareeb DA Abstract Hepatitis C virus infection and its complications are among the leading public health challenges, the emergence of drug-resistant variants is expected to be a major problem. A combinatorial small interfering RNA (siRNA) could be a novel triple therapy that could be suitable for genotype 4. HCV believed to be hepatotropic, but there is liable evidence about its replication in peripheral blood mononuclear cells (PBMC) of chronic HCV infected patients. These cells act as an extra-hepatic reservoir for viral recurrence and persistence, patients with HCV-RNA in PBMC showed a significantly lower response to therapy. The aim of this study to test the efficacy of SiRNA against HCV-4 replication in PBMC in vitro, in order to introduce an alternative therapeutic option for HCV-4 suitable to eradicate it from its reservoir. In the present method, efficacy of synthesized siRNA molecule that target 5/UTR of domain IIIC within IRES of HCV RNA to eradicate HCV intra-PBMC in vitro was tested and compared with IFN/RBV in vitro by using both qRT-PCR and western blot. Sixty genotype-4 chronic HCV patients who are treatment naïve, were enrolled and tested for presence of HCV intra-PBMC using qRT-PCR before and after siRNA treatment in vitro. Resu...
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research